Ghost Tree Capital’s Aldeyra Therapeutics ALDX Stock Holding History

Ghost Tree Capital’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-700,000	Closed	-$5.34M	–	47
2021 Q3	$6.15M	Buy	700,000 +100,000	+17%	+$918K	1.8%	19
2021 Q2	$6.8M	Sell	600,000 -50,000	-8%	-$601K	1.87%	17
2021 Q1	$7.72M	Hold	650,000	–	–	1.81%	19
2020 Q4	$4.46M	Sell	650,000 -600,000	-48%	-$4.21M	0.99%	29
2020 Q3	$9.26M	Buy	1,250,000 +250,000	+25%	+$1.61M	2.68%	10
2020 Q2	$4.17M	Buy	+1,000,000	New	+$3.65M	1.1%	31

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

TLP

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Ghost Tree Capital's ALDX Position: Q4 2021 in Review

Ghost Tree Capital sold out of Aldeyra Therapeutics (ALDX) in Q4 2021, closing a stake of 700,000 shares — an estimated $5.34M sold.

Ghost Tree Capital first reported a position in ALDX in Q2 2020 and held it in 6 quarters. The position peaked at $9.26M in Q3 2020. 115 funds tracked by Wall St. Rank hold ALDX as of Q4 2021.

Ghost Tree Capital reported no remaining Aldeyra Therapeutics position as of Q4 2021 after selling out during the quarter.
Ghost Tree Capital sold 700,000 Aldeyra Therapeutics shares in Q4 2021, an estimated $5.34M.
Ghost Tree Capital first reported a position in Aldeyra Therapeutics in Q2 2020 and held it in 6 quarters.
Ghost Tree Capital's Aldeyra Therapeutics position peaked at $9.26M in Q3 2020.
115 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2021.

Based on Ghost Tree Capital's 13F filing for Q4 2021, filed 16 Feb 2022.